Rhumbline Advisers reduced its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 3.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 286,347 shares of the company’s stock after selling 9,864 shares during the period. Rhumbline Advisers’ holdings in Henry Schein were worth $17,212,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc boosted its stake in Henry Schein by 0.6% in the third quarter. Vanguard Group Inc now owns 16,264,736 shares of the company’s stock worth $1,382,990,000 after purchasing an additional 89,166 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Henry Schein by 4.6% during the fourth quarter. BlackRock Inc. now owns 11,118,102 shares of the company’s stock valued at $872,993,000 after acquiring an additional 488,210 shares during the period. Atlanta Capital Management Co. L L C lifted its stake in shares of Henry Schein by 113.9% during the fourth quarter. Atlanta Capital Management Co. L L C now owns 6,254,807 shares of the company’s stock valued at $491,127,000 after acquiring an additional 3,330,154 shares during the period. Geode Capital Management LLC lifted its stake in shares of Henry Schein by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 2,105,314 shares of the company’s stock valued at $165,038,000 after acquiring an additional 161,542 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Henry Schein by 6.1% during the fourth quarter. Northern Trust Corp now owns 1,914,905 shares of the company’s stock valued at $150,358,000 after acquiring an additional 110,158 shares during the period.
In other news, Director Philip A. Laskawy sold 3,591 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $59.12, for a total value of $212,299.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Philip A. Laskawy sold 1,084 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $59.86, for a total value of $64,888.24. Following the completion of the sale, the director now directly owns 32,899 shares of the company’s stock, valued at $1,969,334.14. The disclosure for this sale can be found here. Company insiders own 1.06% of the company’s stock.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.76 by $0.04. Henry Schein had a return on equity of 18.35% and a net margin of 4.10%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the firm posted $0.95 earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 3.45 EPS for the current year.
Several equities analysts have recently issued reports on HSIC shares. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Wednesday, January 30th. ValuEngine lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. BidaskClub raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, February 7th. Guggenheim began coverage on Henry Schein in a research note on Wednesday, April 17th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Craig Hallum cut their target price on Henry Schein from $96.00 to $72.00 and set a “buy” rating on the stock in a research note on Tuesday, February 19th. Six research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $76.71.
TRADEMARK VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Holdings Reduced by Rhumbline Advisers” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/14/henry-schein-inc-hsic-holdings-reduced-by-rhumbline-advisers.html.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: What is a trade deficit?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.